INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA

Background: Patients with heart failure and reduced ejection fraction (HFrEF) commonly show signs of systemic inflammation. Interleukin-1 (IL-1) is a pro-inflammatory cytokine, known to modulate cardiac function. We aimed to determine the effects of treatment with anakinra, recombinant IL-1 receptor antagonist (IL-1Ra), on plasma IL-1Ra levels. Methods: ). Results: >0.05). Conclusions: ).

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-04-25
DOI
https://doi.org/10.64898/2026.04.17.26351024
Primary Topic
Adipokines, Inflammation, and Metabolic Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA

Chantel McSkimming, Eleonora Mezzaroma, Pratyush Narayan, Stefano Toldo et al.
medRxiv
Adipokines, Inflammation, and Metabolic Diseases
article

INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA

Chantel McSkimming, Eleonora Mezzaroma, Pratyush Narayan, Stefano Toldo, Jazmin Kelly, Michele Golino, J M Canada, Adolfo Mauro, Cory Trankle, Benjamin W. Van Tassell, Antonio Abbate, Andrea Roscioni
article en

Abstract

Background: Patients with heart failure and reduced ejection fraction (HFrEF) commonly show signs of systemic inflammation. Interleukin-1 (IL-1) is a pro-inflammatory cytokine, known to modulate cardiac function. We aimed to determine the effects of treatment with anakinra, recombinant IL-1 receptor antagonist (IL-1Ra), on plasma IL-1Ra levels. Methods: ). Results: >0.05). Conclusions: ).

medRxiv
Virginia Commonwealth University (US), University of Virginia (US)
Kiniksa Pharmaceuticals, Novo Nordisk, National Heart, Lung, and Blood Institute
Good health and well-being
Openalex Percentile: Top 13%
Adipokines, Inflammation, and Metabolic Diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA — Chantel McSkimming, Eleonora Mezzaroma, et al. · medRxiv (2026) | TGRS Research Map | TGRS